AbbVie Inc. (ABBV) — Stock Price, Chart & Analysis
AbbVie Inc. (ABBV) is a Healthcare stock currently trading at $265.71, up 15.52% on the day. It carries a market capitalization of $468.66B and a trailing P/E ratio of 74.71. Over the past 52 weeks, ABBV has traded between $190.75 and $267.47. AbbVie Inc. pays a dividend yielding 2.6%. View the live ABBV chart, technical opinion, analyst ratings, fundamentals and latest news below.
AbbVie Inc. (ABBV) key data
| Price | $265.71 |
| Change (today) | +15.52% |
| Previous close | $230.01 |
| Market cap | $468.66B |
| P/E ratio (TTM) | 74.71 |
| EPS (TTM) | $3.55 |
| Dividend yield | 2.6% |
| 52-week high | $267.47 |
| 52-week low | $190.75 |
| Beta | 0.28 |
| Avg. volume | 6.18M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
Frequently asked questions about AbbVie Inc. (ABBV)
How much does one share of AbbVie Inc. cost?
As of the latest update, one share of AbbVie Inc. (ABBV) trades at $265.71 (+15.52% today).
What is AbbVie Inc.'s market cap?
AbbVie Inc. has a market capitalization of approximately $468.66B.
What is AbbVie Inc.'s P/E ratio?
AbbVie Inc. has a trailing price-to-earnings (P/E) ratio of 74.71.
What is AbbVie Inc.'s earnings per share (EPS)?
AbbVie Inc.'s trailing twelve-month EPS is $3.55.
Does AbbVie Inc. pay a dividend?
Yes — AbbVie Inc. pays a dividend with a yield of 2.6% ($6.92 per share annually).
What is AbbVie Inc.'s 52-week trading range?
Over the past year, ABBV has traded between $190.75 and $267.47.
What is the analyst price target for AbbVie Inc.?
The mean analyst price target for AbbVie Inc. is $278.61. This is informational only and not investment advice.
Latest AbbVie Inc. (ABBV) news
- AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still MattersNews · Sep 22, 2026
- Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)News · Sep 22, 2026
- AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead OptimizationNews · Sep 22, 2026
- AbbVie Secures EU Approval for Rinvoq in Juvenile ArthritisNews · Sep 22, 2026
- AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?News · Sep 22, 2026
- AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic ArthritisNews · Sep 22, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live ABBV dashboard…